Arvinas (ARVN) News
NASDAQ: ARVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
6.46-0.28 (-4.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARVN news summary
We found 12 recent headlines mentioning Arvinas (ARVN): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, ARVN is down 4.15% at $6.46. The most recent story, "Arvinas to Present at Jefferies Global Healthcare Conference", was published by GlobeNewswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Arvinas headlines
- Arvinas to Present at Jefferies Global Healthcare ConferenceNEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today…GlobeNewswire
- Arvinas (ARVN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Arvinas, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateArvinas, Inc. reported its financial results for the quarter ended September 30, 2026. The company reported revenue of $0.5 million for the quarter, compared with $41.9 million for the quarter ended…NasdaqARVN, UHAL.B
- Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation –GlobeNewswire
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation –GlobeNewswire
- Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today…GlobeNewswire
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.NasdaqKYMR, ARVN, NRIX
- Roche Gets FDA Approval for Enspryng in Thyroid Eye DiseaseRHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.NasdaqHALO, ARVN, HOWL
- KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.NasdaqKRYS, HALO, ARVN, HOWL
- Reasons Why Investors Should Consider Betting on Arvinas StockARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.NasdaqARVN, PFE, RIGL
- Can KT-621 Mark a Turning Point for Kymera Therapeutics?KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.NasdaqKYMR, ARVN, NRIX
- Is Kymera Therapeutics Poised for a Breakthrough With KT-621?Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.NasdaqKYMR, ARVN, NRIX